Evidence map›Paper›PMID 36851090›Full record

ReviewVaccines2023

COVID-19 Vaccination in Pediatrics: Was It Valuable and Successful?

Mohamed Ahmed Raslan, Sara Ahmed Raslan, Eslam Mansour Shehata, Amr Saad Mahmoud, Nagwa A Sabri, Khalid J Alzahrani, Fuad M Alzahrani, Saleh Alshammeri, Vasco Azevedo, Kenneth Lundstrom and 1 more

Abstract readReview
In one paragraph

Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Parents' views on pediatric COVID-19 vaccine in Saudi Arabia.Journal of family medicine and primary care · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohamed Ahmed RaslanDrug Research Centre, Cairo P.O. Box 11799, Egypt.ORCID 0000-0003-1039-9230
Sara Ahmed RaslanDrug Research Centre, Cairo P.O. Box 11799, Egypt.
Eslam Mansour ShehataDrug Research Centre, Cairo P.O. Box 11799, Egypt.
Amr Saad MahmoudDepartment of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo P.O. Box 11566, Egypt.
Nagwa A SabriDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo P.O. Box 11566, Egypt.
Khalid J AlzahraniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.ORCID 0000-0002-6688-0106
Fuad M AlzahraniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.ORCID 0000-0001-6930-5214
Saleh AlshammeriDepartment of Optometry, College of Applied Medical Sciences, Qassim University, P.O. Box 6688, Buraydah 51542, Saudi Arabia.ORCID 0000-0002-0179-0767
Vasco AzevedoDepartment of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-4775-2280
Kenneth LundstromPanTherapeutics, Route de Lavaux 49, CH1095 Lutry, Switzerland.
Debmalya BarhDepartment of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-2557-7768

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe mass vaccination of children against coronavirus 2019 disease (COVID-19) has been frequently debated. The risk-benefit assessment of COVID-19 vaccination versus infection in children has also been debated.

aimThis systematic review looked for answers to the question "was the vaccination of our children valuable and successful?".

methodsThe search strategy of different articles in the literature was based on medical subject headings. Screening and selection were based on inclusion/exclusion criteria. RESULTS AND DISCUSSION: The search results revealed that the majority of the reported adverse events after COVID-19 vaccination in pediatrics were mild to moderate, with few being severe. Injection site discomfort, fever, headache, cough, lethargy, and muscular aches and pains were the most prevalent side effects. Few clinical studies recorded significant side effects, although the majority of these adverse events had nothing to do with vaccination. In terms of efficacy, COVID-19 disease protection was achieved in 90-95% of cases for mRNA vaccines, in 50-80% of cases for inactivated vaccines, and in 58-92% of cases for adenoviral-based vaccines in children and adolescents.

conclusionsBased on available data, COVID-19 immunizations appear to be safe for children and adolescents. Furthermore, multiple studies have proven that different types of vaccines can provide excellent protection against COVID-19 in pediatric populations. The efficacy of vaccines against new SARS-CoV-2 variants and the reduction in vaccine-related long-term adverse events are crucial for risk-benefit and cost-effectiveness assessments; therefore, additional safety studies are required to confirm the long-term safety and effectiveness of vaccinations in children.

Indexed as

adverse eventsCOVID-19efficacypediatricssafetytypesvaccination

Identifiers

PMID36851090
PMCPMC9964251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.